Major NHS Study Aims to Transform Treatment for Severe Mental Illness
A groundbreaking research initiative supported by 10 NHS trusts could revolutionise the understanding and treatment of severe mental health conditions, potentially benefiting thousands of patients across England and Wales. The three-year GlobalMinds project is actively recruiting 49,000 participants to develop personalised treatments for disorders such as schizophrenia, bipolar disorder, and severe depression.
Unprecedented Data Collection for Personalised Care
Eligible patients with severe depression and psychosis will be identified and contacted through NHS England's innovative DigiTrials service. Participants will receive comprehensive at-home sampling kits that enable researchers to combine genetic data from blood or saliva samples with detailed questionnaire responses and existing NHS medical records. This integrated approach aims to create the first large-scale dataset linking genetic information with routine clinical data specifically for mental health conditions.
Dr Adrian James, NHS England's national medical director for mental health and neurodiversity, emphasised the transformative potential of this research. "This major new study could transform our understanding of severe mental illness and lead to the dawn of a new era of personalised treatments for patients with conditions including schizophrenia and severe depression," he stated. "People living with a severe mental illness are affected by their condition every day, and it can often lead to preventable physical conditions and shorter lifespans."
Collaborative Research with International Ambitions
The study represents a significant collaboration between mental health data science company Akrivia Health and Cardiff University, with initial implementation in England and Wales and plans for international expansion. Approximately 2,000 patients have already enrolled in the programme, with an additional 1,000 individuals with dementia also participating to broaden the research scope.
Professor James Walters of Cardiff University, serving as chief investigator for GlobalMinds, highlighted the study's ambitious goals. "Precision medicine has already revolutionised the treatment of cancer and other rare diseases and we want GlobalMinds to bring the same breakthroughs to mental health," he explained. "By creating the first large-scale dataset linking both genetic and detailed routine clinical information, GlobalMinds will unlock a new era of personalised mental health care, so we can help tackle the global mental health crisis."
Addressing Growing Mental Health Challenges
The research initiative comes at a critical time as mental health challenges continue to increase across the population. According to mental health charity Mind, approximately one in five adults in England experience common mental health conditions such as anxiety or depression during any given week. Furthermore, the percentage of people reporting severe mental health symptoms has risen significantly from 7% in 1993 to nearly 12% in 2023/24.
Brian Dow, deputy chief executive of Rethink Mental Illness, praised the collaborative nature of the study. "This research has genuine potential to deepen our understanding and open the door to a new generation of treatments for mental illness," he noted. "The strength of the study lies in the partnership between researchers, the NHS and charities like ours, which means data can be powerfully fused with lived experience, with the voices of people experiencing mental illness remaining front and centre."
The GlobalMinds project represents a significant step forward in mental health research, leveraging advanced data collection methods and collaborative partnerships to potentially transform how severe mental illnesses are diagnosed and treated across the healthcare system.
